Skip to content

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05723978
Enrollment
520
Registered
2023-02-13
Start date
2011-01-01
Completion date
2022-12-01
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Pancreatic Ductal

Brief summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

Interventions

PROCEDURESelective extended dissection of pancreaticoduodenectomy

An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

\- 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery. 2\) Patients received radical surgery (R0) and had complete photos or videos of the operation.

Exclusion criteria

\- 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection. 2\) Patients with incomplete clinical, pathological, imaging and follow-up information.

Design outcomes

Primary

MeasureTime frame
Disease-free survival (DFS)From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026